Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.10p -0.96% 112.90p 112.90p 113.00p 116.10p 112.60p 115.50p 1,663,674 16:29:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 126.5 -40.1 -5.3 - 766.98

Vectura Share Discussion Threads

Showing 5876 to 5897 of 5900 messages
Chat Pages: 236  235  234  233  232  231  230  229  228  227  226  225  Older
DateSubjectAuthorDiscuss
17/8/2017
15:26
Diesel Was thinking you could be right with trend reverse then down we go again hey ho that's life.
pooroldboy55
17/8/2017
11:37
Worth reading the whole Hikma piece, sounds positive to me working with the FDA to resolve issues. POB, think this may be one of the days when the trend reverses...
diesel
17/8/2017
10:39
The issues around Advair appear to be related to QA procedures as the industry is highly regulated though not tightly standardized as for example the auto industry (via TS 16949). Meeting the requirements can be subjective and an auditor who is a stickler to his/her opinion can hold things up for a while though I have no doubt the issues are not insurmountable and it should all be resolved in due course and approval granted.
rogerrail
17/8/2017
10:22
Pob-the news about the Advair generic is that it is not dead yet but no indication as to whether it will ever get approval so I'm not surprised that the rally didn't last. VEC's results are out soon, I do hope they don't get the same reaction that Hikma's have today.
alexchry
17/8/2017
09:58
Well good news didn't last long
pooroldboy55
17/8/2017
08:15
Certain degree of clarity here and encouragement.
a0148009
17/8/2017
07:24
From Hikma's half year report this morning: "Since then we, supported by our partner Vectura, have had constructive discussions with the FDA and we have been able to clarify and resolve a number of the questions raised. The discussions with the FDA have confirmed our initial assessment that there are no material issues regarding the substitutability of the proposed device. We are in ongoing discussions with the FDA to address the remaining questions and will provide a more detailed update to the market as soon as we are able to do so." So perhaps not quite the dead duck that we had thought, but no detail on what the real issues are/were.
popper joe
16/8/2017
09:50
cumnor wrote 'Not sure what Hik's performance has to do with Vec? Advair old news more than priced in as we all know and written off by the market'. It certainly seems like the market has written off the Advair generic, the share price was around 160p when the market started to worry about FDA approval after Mylan got knocked back. However, I don't think that VEC and HIK have written off the generic just yet so I am interested in Hik's results in case there is an update on progress with the FDA. If cumnor is right and the generic is a dead duck then I think it will be quite a while before the share price reaches the heights of earlier in the year much less the optimistic forecasts of some of the analysts.
alexchry
16/8/2017
08:35
Still here Diesel. I've learned not to get too excited about news flow. I still believe VEC will come good, but in a slow burn kind of way. It's definitely a positive announcement this morning, hopefully one small increment of many more to come.
saxula
16/8/2017
08:25
Quiet here, everyone moved on? Some positive news this morning, and tomorrow Hikma results, may here something about Advair generic.
diesel
14/8/2017
11:44
Interesting article in Business section of Sunday Times. Won't quote it all but basically, Mylan, who have a generic asthma drug that did not get approval have announced that they do not need to do any more trials, raising the green light that Hikma also may not need to do further trials to gain approval for their/our generic. Should here something from Hikma this week.
diesel
10/8/2017
10:09
i sold out a couple of weeks ago, just can't see a recovery in share price so cut my losses and moved on to more attractive targets (INSE, GMAA,PTSG & XLM if anyone's interested)
harry the haddock
09/8/2017
13:39
You may be right...it is so sad. I have held VEC since 2013 on basis of deal with Novartis. However i have now lost patience with VEC and will sell out today or tomorrow and invest in something less boring. Need to see a positive trend line up before considering again.
jdgen
09/8/2017
09:14
Slowly but surely going under a pound! !!
pooroldboy55
08/8/2017
20:09
Not sure what Hik's performance has to do with Vec? Advair old news more than priced in as we all know and written off by the market?
cumnor
08/8/2017
20:08
Not sure what Hik's performance has to do with Vec? Advair old news more than priced in as we all know and written off by the market?
cumnor
08/8/2017
19:06
I think the fundamentals showed generic advair was worth about 15p on the share price, so a fall of around 50p to where we are now would suggest that the market has completely discounted it, and some!
popper joe
08/8/2017
16:44
Hikma fell over 6% today which seems rather ominous. Their results are due on the 17th, will be interested to hear what they say about Advair generic. What I would like to know is what price the analysts would put on VEC assuming the Advair generic never comes to market.
alexchry
01/8/2017
13:08
I've just noticed the posts here highlighting HDB's reduction in holding from 16.1% on June 30 '16 to 8.5% on June 30 '17. I looked back at the RNS since mid June '16, and HDB have only announced a change in holdings twice in that period. Both announcements (16Jan'17 & 6April'17) announce a small change from just above 10% to just below 10%. Does anyone know why there are not more RNS recording the stages in the significant reduction in their holding?
gnnmartin
01/8/2017
12:20
Looks to me like there is a seller that has to be cleared. Large sells in end of day auction for a few weeks. imo
qackers
01/8/2017
10:31
Continuing good results on Flutiform sales in Japan, with Q1 sales of Y2.8B on target to hit Y5.4B for H1 and Y12Billion (£82m) for FY. VEC has a product supply agreement in addition to royalties
rogerrail
31/7/2017
17:34
AGREE Back to normal up am down pm problem is the only thing that gets stiff these day's is my back !!!!!
pooroldboy55
Chat Pages: 236  235  234  233  232  231  230  229  228  227  226  225  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170817 21:29:11